my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
26-06-2012: Savira pharmaceuticals GmbH, a spin-off of the European Molecular Biology Laboratory (EMBL), has signed a collaboration and license agreement with Roche, thus further strengthening the links between fundamental research and major pharmaceutical development companies.
This partnership should promote the joint development of new and innovative drug-candidates to fight both seasonal and pandemic influenza. It is based on research by Stephen Cusack, Head of EMBL Grenoble, and colleagues Darren Hart and Rob Ruigrok of the joint EMBL-Grenoble University-CNRS Unit for virus host cell interactions (UVHCI). They study the unique mechanism of how the influenza virus replicates, known as "cap-snatching", and the detailed architecture of the various molecules involved.
Cap-snatching is one of the mechanisms used by the virus to hijack the protein-production machinery of the infected host cell so that it preferentially produces viral proteins. It is performed by a viral enzyme called polymerase. Small molecule inhibitors of the polymerase targeting the cap-snatching mechanism can block viral replication and thus prevent the infection from spreading. Because this mechanism is used by all influenza strains, such inhibitors could potentially help fight a wide range of flu viruses, including novel pandemic strains.
Savira will provide Roche with an exclusive, worldwide license on its cap-snatching inhibitor programme in exchange for milestone payments that could total EUR 240 million, in addition to upfront payments, research and development support, and royalties on product sales.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Mature cells can be reprogrammed to pluripotency and thus regain the ability to divide and differentiate into specialized cell types. Although these so-called induced pluripotent stem cells (iPS cells) represent a milestone in stem cell research, many of the biochemical processes that under ... more
Savira pharmaceuticals GmbH, a spin-off of the European Molecular Biology Laboratory (EMBL), has signed a collaboration and license agreement with Roche, thus further strengthening the links between fundamental research and major pharmaceutical development companies.This partnership should ... more
New resource opens the door for enzyme research
The European Molecular Biology Laboratory's European Bioinformatics Institute has launched the Enzyme Portal, a freely available resource for people who are interested in the biology of enzymes and proteins with enzymatic activity.The Enzyme Portal mines and displays data about proteins wit ... more
European Molecular Biology Laboratory (EMBL)
EMBL is an inter-governmental organisation currently led by the Director General, Prof. Iain Mattaj, appointed by the EMBL Council. The Council is composed of all 20 Member States one associate member state of the Laboratory. Each Member State is represented by up to two delegates, who may ... more
European Molecular Biology Laboratory (EMBL)
The European Molecular Biology Laboratory is a non-profit organisation and a basic research institute funded by public research monies from 20 member states and one associate member. Research at EMBL is conducted by approximately 85 independent groups covering the spectrum of molecular biol ... more
FDA clears Roche's vitamin D laboratory test
Roche announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated vitamin D test for use on cobas modular platforms, further expanding the company’s bone metabolism test menu. Vitamin D is an important building block for human health and i ... more
Savira pharmaceuticals GmbH, a spin-off of the European Molecular Biology Laboratory (EMBL), has signed a collaboration and license agreement with Roche, thus further strengthening the links between fundamental research and major pharmaceutical development companies.This partnership should ... more
Roche Steps Back from Illumina Acquisition
F. Hoffman-La Roche dropped its bid to buy Illumina after Illumina’s shareholders made it clear at the company’s annual meeting that the terms were inadequate. Roche had made a $51 per share tender offer for San Diego-based Illumina, but allowed the offer to expire. GlobalData analyzed the ... more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
